Independent Effect of Depression and Anxiety on Chronic Obstructive Pulmonary Disease Exacerbations and Hospitalizations (original) (raw)
Related papers
Depression and Anxiety in cases of COPD
IP Innovative Publication Pvt. Ltd, 2017
Patients with chronic obstructive pulmonary disease (COPD) have many times under-recognized and untreated depression and anxiety symptoms which lead to harmful effects on physical functioning and social interaction. Depression and anxiety are often difficult to identify in patients of COPD. The causes for these associated diseases in COPD are multifactorial including social, behavioural and biological factors. Less than 35% of COPD patients with these co-morbid diseases are receiving appropriate treatment. The factor for this low treatment rate includes patients perceived barrier e.g. reluctance to receive antidepressant drug therapy, poor treatment compliance and deficiency of standardized diagnostic approach. There are inconclusive evidence to support the efficacy of anti-depressant drug therapy in patients of COPD with comorbid depression and anxiety. Promising results are being noticed in pulmonary rehabilitation, psychological therapy and the collaborative care model in reducing depression and anxiety symptoms in patients with COPD. But, the main limitations are short term follow up period. More research is required to establish the efficacy of these interventions in randomized control trial with larger samples and longer follow up periods.
Depression and anxiety in patients with COPD
Under-recognised and untreated depression and anxiety symptoms have deleterious effects on physical functioning and social interaction increasing fatigue and healthcare utilisation in patients with chronic obstructive pulmonary disease (COPD). Depression and anxiety are challenging to identify and treat because their symptoms often overlap with those of COPD. The cause(s) of depression and anxiety symptoms are multifactorial and include behavioural, social and biological factors. Less than one-third of COPD patients with comorbid depression or anxiety symptoms are receiving appropriate treatment. Factors that contribute to the lack of provision of treatment are varied, they include patient perceived barriers, for example lack of knowledge and reluctance to receive antidepressant drug therapy; poor treatment compliance and lack of a standardised diagnostic approach; and scarcity of adequate resources for mental health treatment.
Anxiety and depression-Important psychological comorbidities of COPD
Journal of thoracic disease, 2014
Anxiety and depression are common and important comorbidities in patients with chronic obstructive pulmonary disease (COPD). The pathophysiology of these psychological comorbidities in COPD is complex and possibly explained by common risk factors, response to symptomatology and biochemical alterations. The presence of anxiety and/or depression in COPD patients is associated with increased mortality, exacerbation rates, length of hospital stay, and decreased quality of life and functional status. There is currently no consensus on the most appropriate approach to screening for anxiety and depression in COPD. Treatment options include psychological [relaxation, cognitive behavioural therapy (CBT), self-management] and pharmacological interventions. Although there is some evidence to support these treatments in COPD, the data are limited and mainly comprised by small studies. Pulmonary rehabilitation improves anxiety and depression, and conversely these conditions impact rehabilitation...
Impact of Anxiety and Depression on Chronic Obstructive Pulmonary Disease Exacerbation Risk
American Journal of Respiratory and Critical Care Medicine, 2012
Chronic obstructive pulmonary disease (COPD) exacerbations contribute significantly to morbidity and mortality. COPD is also associated with high levels of psychological distress, which has been linked with higher exacerbation rates. At a recent American Thoracic Society conference symposium titled "Depression and Obstructive Lung Disease: State of the Science and Future Directions" held in 2010 in New Orleans, clinicians and researchers identified a number of important research priorities related to psychiatric comorbidities, including the need to better understand their impact on COPD outcomes, such as exacerbations. This article reviews the current literature and quantifies the prospective impact of anxiety and depression on exacerbation risk in patients with COPD. The limitations of the existing literature and the perspectives for future research are addressed.
Relationship between depression and exacerbations in COPD
European Respiratory Journal, 2008
Chronic obstructive pulmonary disease is associated with exacerbations. Some patients are prone to frequent exacerbations and these individuals have a worse quality of life, greater limitation of their daily activity and faster disease progression than patients with less frequent exacerbations.
Anxiety and Depression in COPD
CHEST Journal, 2008
Background-Approximately 60 million people in the United States live with one of four chronic conditions: heart disease, diabetes, chronic respiratory disease, and major depression. Anxiety and depression are very common comorbidities in COPD and have significant impact on patients, their families, society, and the course of the disease.
Depression, Anxiety and Stress among COPD Patients: A Comparative Cross Sectional Study
2020
Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with depression, anxiety and stress, which are the commonest disorders resulting in significant morbidity and mortality. There is paucity of information regarding the association between depression, anxiety, and stress and chronic obstructive pulmonary disease in the present setup. This comparative cross-sectional study was designed to determine the magnitude of Depression, Anxiety and Stress and associated factors among COPD patients. Methods: Sixty five COPD patients and equal number of age and sex matched healthy individuals were included in the study. The study was conducted at Jimma University Specialized Hospital JUSH), from March 01 to April 30/2016. Spirometric assessment was done to evaluate severity of COPD. Depression, anxiety and stress scale (DASS 21) was used for the assessment of severity of depression, anxiety and stress. Chi-square test, independent t-test, Fisher’s exact test, one way ANOVA and ...
Self-reported depression and anxiety among COPD patients. A case-control study
Sao Paulo Medical Journal, 2022
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death worldwide. 1 It is a major cause of chronic morbidity and mortality throughout the world. Many people die prematurely from it or its complications. 2 COPD is defined as a respiratory disease, mainly caused by tobacco abuse and characterized by persistent symptoms such as chronic cough with or without expectoration and chronic airflow limitation, that usually manifests as progressive dyspnea. 3 According to the World Health Organization (WHO), common mental disorders refer to two main diagnostic categories: depressive disorders and anxiety disorders. Both of these are highly prevalent in the population and can affect people of all ages. Over 300 million people are estimated to suffer from depression, equivalent to 4.4% of the world's population, and this number seems to be increasing. 3 Depressive disorders are characterized by symptoms such as sadness, loss of interest or pleasure, feelings of worthlessness or guilt, sleep difficulties, fatigue, appetite or weight changes, feelings of tiredness, psychomotor disturbances, poor ability to concentrate and even suicidality. 4 Depression can be long-lasting or recurrent, and causes impairment to activities of daily life. Anxiety is associated with physical and psychological discomfort. All anxiety disorders share common symptoms, such as fear, anxiety and avoidance. Other anxiety-related symptoms include fatigue, restlessness, irritability, sleep disturbances, reduced concentration, lack of memory and muscle tension. Depression and anxiety often co-occur. Up to 90% of patients with anxiety develop symptoms of depression, and nearly 85% of patients with depression show some kind of anxiety symptom. 5,6 The prevalence of depression and anxiety is two to three times higher among people with chronic medical conditions than among healthy people. 7 People with a long-term condition and
Journal of clinical and diagnostic research : JCDR, 2017
Anxiety and depression are important but often under-diagnosed co-morbid conditions in patients with Chronic Obstructive Pulmonary Disease (COPD) which may affect the functional capacity of the patients. To find out the proportion of depression and anxiety among stable COPD patients using a validated questionnaire suitable for use in clinic and the factors affecting their reduced functional capability as assessed by six-minute walk test. This was a descriptive cross-sectional study. Seventy five patients diagnosed with stable COPD in outpatient Department of Pulmonary Medicine in a tertiary care hospital, satisfying all inclusion criteria, were included in the study. They were examined clinically, categorized as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity assessment guideline and interviewed by designated interviewer using validated questionnaire for depression (Hamilton depression rating scale, HAM-D) and anxiety (State Trait Anxiety Inventory, STAI)....